Biotech

All Articles

Ascendis' dwarfism medication favorites in stage 3, threatens BioMarin

.Ascendis Pharma has actually become a possible danger to BioMarin's Voxzogo, disclosing stage 3 dev...

Despite ph. 3 miss, Alkeus sees road ahead for eye disease resource

.Though Alkeus Pharmaceuticals' oral eye illness property neglected to substantially decrease geogra...

Kairos goes social along with $6M IPO to fund trials of cancer cells drug

.With a triad of biotechs hitting the Nasdaq on Friday, it was quick and easy to miss a smaller-scal...

Vaccine and Keytruda combo reliable in squamous cell cancer

.Immune gate preventions are the superheroes of cancer treatment. Medicines like Bristol Myers Squib...

Cue Biopharma mark time J&ampJ veterinarian as CBO-- Chutes &amp Ladders

.Welcome to recently's Chutes &amp Ladders, our roundup of substantial management hirings, firings a...

Regeneron's Opdualag rival presents 57% response rate

.Regeneron is back along with lasting consequence for its LAG-3 prevention and PD-1 prevention combi...

AstraZeneca blog posts records on in-house rivals to AbbVie, Pfizer ADCs

.AstraZeneca has actually discussed an early consider the efficiency of its own in-house antibody-dr...

iTeos- GSK's TIGIT star presents significant improvement

.After introducing a period 3 launch based on good midstage end results, iTeos and also GSK are actu...

More joint FDA can speed up uncommon illness R&ampD: file

.The FDA should be actually a lot more available and also collective to discharge a surge in commend...

Zenas, MBX, Bicara head to Nasdaq in warm time for biotech IPOs

.It is actually an extraordinarily occupied Friday for biotech IPOs, with Zenas BioPharma, MBX and B...